A randomized, controlled trial was conducted to evaluate the impact of a directly administered antiretroviral therapy program (DAART) and intensive adherence case management (IACM) intervention on virologic and immunologic response to highly active antiretroviral therapy (HAART) among patients at 3 public human immunodeficiency virus clinics in Los Angeles County, California.
for the majority of HIV-infected persons in the United States [1] [2] [3] [4] . Research suggests that HIV-infected persons must ingest at least 90% of their HAART doses for adequate viral suppression [1, 5, 6 ]-a proportion of doses higher than that necessary for most other diseases [4] . Studies in primary care settings suggest that, on average, 50% of patients achieve a viral load less than the limit of detection after 6 months of HAART [2, 7] , and suboptimal HAART adherence is cited as one of the major explanations for the absence of viral suppression [1, 3, 5, 7] .
To address patient adherence challenges, clinic-and community-based interventions designed to improve adherence to HAART have become widespread in recent years [2] . Adherence-support programs for HAART have included (1) those based on experience with directly observed therapy for tuberculosis, in which trained personnel make personal visits to deliver HAART and to observe the ingestion of pills [8] [9] [10] ; (2) cognitive interventions designed to provide education and instruction regarding HAART adherence [11] [12] [13] [14] ; (3) behavioral interventions designed to influence adherence behavior [16] ; (4) effective interventions that aim to maximize the patient's social and emotional support to improve adherence [17, 18] ; and (5) a combination of the above [4, 15, [19] [20] [21] . Few of these adherence interventions have been examined for improved disease outcomes in randomized, controlled trials that have sufficient statistical power, that have included an adequate follow-up period, or that have included both on-treatment and intent-to-treat analyses [2, 4, 9-11, 15, 18, 21-23] .
In addition, previous evaluations of adherence-support programs have focused on populations with known adherence problems that have included injection drug users [9, 10] and homeless persons [24] , whereas few adherence interventions have been tested in a general low-income clinic population. The evaluation of the efficacy of adherence-support programs in a low-income clinic population is critical to providing data to determine funding priorities among the many ancillary services that are available to low-income persons with HIV infection in the United States and that are funded primarily by the Ryan White Care Act [25] .
The primary objective of this randomized, controlled trial was to determine whether there were clinical benefits to participation in a directly-administered antiretroviral therapy (DAART) intervention or in an intensive adherence case management (IACM) intervention, compared with the standard of care (SOC), for HIV-infected patients at 3 public HIV clinics in Los Angeles County, California. Six-month virologic and immunologic responses to HAART were compared across the 3 study arms and are presented below.
METHODS
Treatment-naive and treatment-experienced persons for whom no more than 1 prior regimen had failed were recruited from 3 public HIV clinics in Los Angeles County from November 2001 through March 2004. Treatment-naive patients were defined as those who initiated their first HAART regimen in the 6 months before study enrollment. Treatment-experienced patients were defined as those who initiated a new HAART regimen in the 6 months before study enrollment because of virologic failure (viral load, 1400 copies/mL) during no more than 1 previous regimen. Study participants had to score у23 on the Folstein Mini Mental Status examination [26, 27] , to live or work within the DAART workers' catchment areas, and to agree to participate if they were randomized to the DAART arm. Persons were ineligible for study entry if they had advanced liver or kidney disease, were receiving directly observed therapy for tuberculosis, or were participating in clinical trials that prohibited participation in an adherence-support program.
The 3 study clinics provide care to 800-2500 patients annually who represent the epidemic in Los Angeles County, with an underrepresentation of white men who have sex with men [28] . In addition to primary care services, the study clinic adherence support included provider adherence counseling at the time of clinic visits, meetings with a case manager every 3-4 months, and access to community-based social support services, including adherence support provided by communitybased pharmacies and others. In addition, during the course of the study, weekly adherence clinics were established by staff uninvolved with the study at the 2 larger clinics at which patients in the SOC arm could receive one-on-one adherence counseling from providers.
Participants were randomized to 1 of 3 arms (the DAART arm, the IACM arm, or the SOC) using a 1:1:1 randomized design with a computer-generated random-number assignment and a blocking factor of 6. Patients were stratified by site and HAART experience, and treatment assignment was concealed from study staff in sealed envelopes. Adherence barriers were not assessed before randomization.
For 6 months, DAART participants received daily delivery of their HAART medications Monday through Friday, and a specially-trained, bilingual community worker observed the participant take 1 daily HAART dose [8] . The community workers delivered evening, weekend, and holiday doses for selfadministration. At the next meeting, patients were queried about the self-administered doses, and empty packages were collected. Adherence problems were addressed immediately by the community worker when possible, and participants were referred to the clinic staff when necessary.
Participants in the IACM arm self-administered their HAART and met weekly for 6 months with a trained case manager to overcome barriers to HAART adherence while also engaging in traditional case-management activities, which included referrals for health care payment issues, housing support, drug abuse treatment, legal services, and nutritional support [20] . Patients randomized to the SOC arm self-administered their HAART and continued to receive the services that were available to all clinic patients, including quarterly contact with a case manager.
Trained study staff extracted data that were collected as part of routine primary care visits, which occurred every 3-4 months. Medical decisions were made by the medical staff regarding antiretroviral treatment regimen, frequency of follow-up visits, and timing of laboratory tests-all of which were nonuniformly influenced by individual patient circumstances and personal schedules. Thus, for determination of virologic and immu-nologic response, we measured the viral load and CD4 + cell count closest to week 26 of follow-up but within either of 2 specified ranges of time (16-26 weeks of follow-up or, for participants who did not undergo testing during the earlier time range, 27-31 weeks of follow-up). Patients were interviewed by telephone by study staff not involved in the intervention 0, 3, and 6 months after enrollment; the interviews regarded selfreported adherence to HAART regimens in the previous 24 h, 3 days, and 7 days [21] .
The primary study outcome was the proportion of patients in the 3 study arms with a viral load of !400 copies/mL (as determined using the Amplicor HIV-1 Monitor Version 1.5 Assay; Roche Diagnostics) at 6 months. We estimated that, if 75 persons were enrolled in each arm, we could detect a difference between 50% in the SOC arm and 75.3% ( ; power p 0.8 a p ) in either intervention arm. Secondary study end points 0.025 included log change in the viral load; change in the CD4 + cell count (as determined using FACScan; Becton-Dickinson) and median CD4
+ cell count; percentage of patients who reported missing no doses of HAART in the previous 24 h, 3 days, and 7 days; and development of a new or recurrent opportunistic infection. Analysis of the virologic end point was conducted using both on-treatment and intent-to-treat analyses; for the latter, participants who had missing values were considered to have had treatment failure [29, 30] . x 2 Analyses and Kruskal-Wallis tests were used to compare differences among the arms using SAS software, version 9.0 (SAS Institute). Institutional review board approval was obtained, and study procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. Informed consent was obtained in English or Spanish by bilingual study staff.
RESULTS
We screened 2797 patients and determined that 416 (15%) were eligible for the study, of whom 166 (40%) declined to participate. For a subset of 20 patients who declined participation but who agreed to complete a survey, the demographic characteristics were very similar to those of the study group. The other 250 patients were enrolled in the study; 82 were randomized to the DAART arm, 84 were randomized to the IACM arm, and 84 were randomized to the SOC arm (table 1) . Most patients were men (75%), were aged у30 years (82%), were nonwhite (64% were Latino and 24% were African American), self-identified as heterosexual (56%), were born outside of the United States (62%), were monolingual Spanish speakers (57%), were unemployed (73%), and reported annual incomes of !$10,000 (64%). The self-reported mode of HIV exposure for men was most commonly sex with men, which included men who have sex with men who also reported injection drug use, and 29% also reported heterosexual sex. Women most often reported exposure to HIV via heterosexual sex (75%). The mean time since original HIV diagnosis (‫ע‬SD) was 4.1 ‫ע‬ 4.4 years; there were no differences in this time between the 3 arms.
One hundred fourteen patients (46%) were treatment naive, and 136 (54%) were treatment experienced (table 2) . Most patients (90%) were prescribed twice-daily HAART regimens at the time of enrollment in the study. There were no differences between the 3 study arms with regard to type of HAART regimen or the median duration of HAART (in weeks) at the time of enrollment. At baseline, the median log viral load was 4.28 log copies/mL (interquartile range, 2.36), 67 patients (27%) had a viral load of !400 copies/mL, and the median CD4 + cell count was 127 cells/mm 3 . Compared with patients in the IACM arm, patients randomized to the DAART arm had higher baseline viral loads and lower CD4 + cell counts, and fewer of these patients had a viral load !400 copies/mL ( for each P ! .05 comparison), but patients in the IACM arm did not differ from patients in the SOC arm ( for each comparison). P 1 .05 One hundred ninety-four (78%) of 250 patients completed 6 months in the study, with equal rates of retention among the 3 arms (table 3) . However, there were differences in the timing of and reasons for dropouts, with more patients in the DAART arm (18%) exiting the study early, compared with those in the SOC arm (4%) (OR, 6.0; 95% CI, 1.7-21.8). Among the DAART patients who exited the study early, the most common reason (40%) was that the intervention required too great a time commitment or that the participant was unable to fit the intervention into his or her schedule. An additional 1% of DAART patients, 13% of IACM patients, and 20% of SOC patients were lost to follow-up in the study during the 6-month follow-up period; the difference between patients in the DAART and SOC arms lost to follow-up was statistically significant ( ), although this finding was based on small numbers P ! .001 of participants.
Biomedical Responses at 6 Months
In an intent-to-treat analysis, no statistical differences were observed in the percentage of patients with undetectable viral load (!400 copies/mL) at 6 months in the DAART group (54%), IACM group (60%), and SOC group (54%; ) (table 3) . P 1 .05 There were also no statistically significant differences between the 3 study arms in the on-treatment analyses, in which 71% of the DAART patients, 80% of the IACM patients, and 74% of the SOC patients had undetectable viral loads at 6 months ( ). No statistical differences were observed at month 6 P 1 .05 in viral load reduction, median CD4 + cell count, change in CD4 + cell count from baseline, or percentage of patients with a CD4 + cell counts !200 cells/mm 3 . In addition, there were no differences between the 3 study arms in the percentage of patients with new or recurrent opportunistic infections. (27) 19 (23) 16 (19) 57 (23) Transgender (male to female) 1 (1) 3 (4) 1 (1) 5 (2) Refused to answer 0 (0)
Age at enrollment
20-29 years 18 (22) 11 (13) 14 (17) 43 (17) 30-39 years 34 (42) 37 (44) 32 (38) 103 (41) 40-49 years 23 (28) 22 (26) 28 (33) 73 (29) у50 years 6 (7) 14 (17) 10 (12) 30 (12) Race/ethnicity 
Adherence to HAART
At enrollment, 138 (84%) of 165 patients reported missing no doses of HAART in the previous 7 days, with no differences among study arms (table 4) . At 6 months, of 96 patients who were contacted for a phone interview, 35 (97%) of 36 patients in the DAART arm, 24 (92%) of 26 in the IACM arm, and 32 (97%) of 34 in the SOC arm reported missing no HAART doses in the previous 24 h. There were also similarities across the 3 arms with regard to self-reported adherence in the 3 and 7 days before the interview. None of the differences in reported adherence were statistically significant. Similar data were found at 3 months (data not shown).
DISCUSSION
No differences were observed in virologic or immunologic outcomes at 6 months for patients who participated in a DAART or an IACM intervention, compared with patients who received SOC treatment, at 3 public HIV specialty clinics in Los Angeles County. These data represent the results from, to our knowledge, the first randomized, controlled trial of DAART and IACM programs in a community-based clinic population to have examined virologic and immunologic outcomes. The likely explanation for the absence of a virologic or immunologic effect of the interventions is that the adherence support provided by the study clinics and other sources adequately addressed the adherence needs of patients. In fact, in the on-treatment analysis, the percentage of SOC patients with an undetectable viral load at 6 months (74%) in this study group is substantially larger than the percentage (∼50%) that was often reported in primary care settings during the late 1990s and early 2000s, when this study was first developed [31] [32] [33] [34] .
The level of adherence support provided by these clinics was 55 (68) 48 (57) 45 (55) 148 (60) 200-500 23 (28) 28 (33) 26 (32) 77 (31) 1500 3 (4) 8 (10) 11 (13) 22 (9 strong and included adherence counseling by providers at the time of patient visits. In addition, at 2 of the 3 study clinics, adherence clinics were instituted independently of the study to provide patients with additional one-on-one adherence counseling. Also, many patients at these clinics obtain their HIV medication prescriptions at private pharmacies that specialize in HIV care and whose services include packaging of medication in pillboxes, medication delivery, and counseling. The results of this study suggest that the primary and ancillary care services currently available to patients at the 3 study clinics provide the adherence support necessary to suppress viral load during the 6 months after initiation of a new HAART regimen among a general clinic population of treatment-naive persons and persons for whom no more than 1 prior HAART regimen has failed.
Previous research on DAART, alternatively referred to as "modified directly observed therapy," has suggested a beneficial effect among populations with documented adherence problems. A small, randomized, controlled trial of DAART versus self-administered therapy among injection drug users in Connecticut reported better adherence among subjects in the DAART group, but the study did not report data on clinical outcomes [35] . An observational study of DAART in a methadone clinic found a significantly larger proportion of DAART patients with a viral load !400 copies/mL at 6 months, compared with a control group, in an intention-to-treat analysis 1400 copies/mL 17 (29) 11 (20) 14 (26) 42 ( (74) 125 (75) 401-1000 1 (2) 4 (7) 2 (4) 7 (4) 1001-10,000
3 (5) 2 (4) 3 (5) 8 (5) 110,000
13 (22) 5 (9) 9 (16) [10], whereas another nonrandomized, noncontrolled trial of a modified directly observed therapy program among an indigent population reported improved disease outcomes at 9 months of follow-up [36] . These data, combined with results from the present study, suggest that DAART may be most beneficial among populations with known adherence problems.
Although it was based on small numbers of patients, another important finding to emerge from this randomized, controlled trial is the statistically larger percentage of patients in the DAART arm who exited the study early, compared with patients in the SOC arm. The most common reason cited for exiting the study early was the large time commitment required by a DAART intervention. Considering the expense required for implementation of a DAART program and the lack of clinical benefit demonstrated here, these data suggest that DAART may not be viable in a low-income, public clinic population. However, more patients were lost to the clinics for other reasons in the SOC arm, compared to the DAART arm, suggesting that the DAART intervention is acceptable to many patients and may improve retention in care for this indigent population. Regardless, the retention rate in the study was modest at 6 months, with nearly one-quarter of the patients dropping out of the study, many of whom were also lost to follow-up at the clinic. This highlights the need to improve retention in care, because, as was demonstrated in this study, if persons who are treatment naive or who have limited prior antiretroviral exposure continue to adhere to their HAART regimens for 6 months, there is a very good chance they can achieve virologic suppression.
Previous research on adherence interventions that are similar to the IACM intervention includes an adequately powered, randomized, controlled trial of an education intervention plus routine counseling that found no viral load or adherence differences between the intervention group and control group, who received only routine counseling at 24 weeks [14] . Another randomized, controlled trial of an educational intervention in France found improvements in adherence rates but no differences in virologic or immunologic outcomes at 6 and 12 months of follow-up [13] . Finally, results from a randomized, controlled trial in an HIV outpatient care setting in Spain showed significantly better adherence rates and viral load suppression at 48 weeks among patients who participated in an educational intervention, compared with patients in an SOC group, although the adherence benefits did not remain in an intention-to-treat analysis [37] . These data on educational adherence interventions among general clinic populations are mixed and point to the need for randomized, controlled trials of these programs that involve sufficiently large sample sizes of patients with known adherence issues to evaluate these interventions. Although the study data presented here showed no positive clinical effects beyond those achieved by the SOC for an adherence-focused case-management intervention, there are clearly other benefits of case-management programs that provide social, financial, and other support services that we have not reported here.
Limitations to this study include a low acceptance rate among eligible participants that was, in part, the result of considerable competition for recruitment with ongoing clinical trials at all 3 clinics. In addition, the study was powered to see large differences (i.e., 125.3%); however a larger sample size would likely not have changed the main findings, because the differences in the point estimates in the intention-to-treat and ontreatment analyses were very small. In addition, there were substantial missing adherence data at 6 months, because the study population is very transient and was often difficult to locate. It is also possible that there was overreporting of selfreported adherence in the study group [38, 39] ; however, this would be expected across all 3 study arms, rendering the comparison of adherence rates valid.
The finding that patients who were receiving therapy and who had a suppressed viral load at study entry were most likely to maintain viral suppression for 6 months may appear to bias the study towards finding no difference, but we had wished to enroll patients who represented the clinic population and not to arbitrarily select patients who would have been at risk for nonadherence. These data actually provide additional support to the importance of stressing to patients that their first course of antiretroviral therapy is their best chance to achieve virologic suppression. In addition, it is possible that 6 months is too early to detect an impact of the 2 adherence interventions on clinical or adherence outcomes.
In summary, no improvements in virologic, immunologic, or adherence-based benefits were observed in the DAART and IACM intervention groups, compared with the SOC group, largely because the response among patients in the SOC group was strong. These data, combined with the findings of previous research, suggest that these adherence-support interventions may be most beneficial to HIV-infected persons with documented adherence problems. Clinics that provide strong, clinicbased adherence-support services and retention of patients can expect to achieve very good clinical results among persons who are antiretroviral naive or who have limited prior treatment experience.
